Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.
Podcast: Play in new window
| Download (Duration: 5:34 — 64.4MB)
Really good, thank you – well delivered and clear.
Great podcast. I will take a step back here. Dr. Oxnard’s piece gives me room for optimism. It seems that targeted therapy continues to make slow but steady forward steps, and I am excited to hear Dr. West’s interpretation on the next ASCO meeting to follow up on Dr. Oxnard’s information here. Chemo and Tarceva seems to have a strong place in treatment with developing resistance. Also, chemo might become, by evolving decision making strategies, eventually a method to “buy time” as targeted therapy gets more sophisticated. Pardon my Pollyanna thinking – it works well when you have stage IV adenocarcinoma. Dr. West, I appreciate the podcasts to capture multiple thought leaders’ take on present and future treatment. My brother worked in Redmond for a nerdy guy named Gates for seven years and told me that my family needed to see Seattle. Hope to do so in seeing you to render a clinical opinion. Again, thank you for all that you do..
Very good presentation. . .Thank you!
You must be logged in to post a comment.